Form 8-K Spyre Therapeutics, Inc. For: May 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
Spyre Therapeutics (SYRE) Enters Licensing Agreement with Paragon over SPY001
May 15, 2024 7:49 AM EDTOn May 14, 2024, Spyre Therapeutics (NASDAQ: SYRE), and Paragon Therapeutics, Inc., a Delaware corporation (Paragon), entered into (i) a license agreement (the SPY001 License Agreement), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies and products targeting 4ß7 integrin and (ii) a license agreement (the SPY002 License Agreement and, together with the SPY001 License Agreement, the License Agreements), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain licensed antibodies and products targeting TL1A,... More
